Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hua Medicine ( (HK:2552) ) has issued an update.
Hua Medicine has announced an updated list of its board of directors effective November 27, 2025. The announcement details the roles and committee memberships of each director, highlighting the strategic leadership structure within the company. This update may influence the company’s governance and strategic direction, impacting stakeholders and potentially enhancing its position in the pharmaceutical industry.
The most recent analyst rating on (HK:2552) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on Hua Medicine stock, see the HK:2552 Stock Forecast page.
More about Hua Medicine
Hua Medicine is a company incorporated in the Cayman Islands, operating within the pharmaceutical industry. It focuses on developing innovative therapies and solutions, particularly in the area of diabetes treatment.
Average Trading Volume: 6,785,616
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.15B
See more insights into 2552 stock on TipRanks’ Stock Analysis page.